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IMPORTANCE The US is currently an epicenter of the coronavirus disease 2019 (COVID-19)
pandemic, yet few national data are available on patient characteristics, treatment, and
outcomes of critical illness from COVID-19.
OBJECTIVES To assess factors associated with death and to examine interhospital variation
in treatment and outcomes for patients with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS Thismulticenter cohort study assessed 2215 adults
with laboratory-confirmed COVID-19 whowere admitted to intensive care units (ICUs) at
65 hospitals across the US fromMarch 4 to April 4, 2020.
EXPOSURES Patient-level data, including demographics, comorbidities, and organ
dysfunction, and hospital characteristics, including number of ICU beds.
MAIN OUTCOMES ANDMEASURES The primary outcomewas 28-day in-hospital mortality.
Multilevel logistic regression was used to evaluate factors associated with death and to
examine interhospital variation in treatment and outcomes.
RESULTS A total of 2215 patients (mean [SD] age, 60.5 [14.5] years; 1436 [64.8%]male;
1738 [78.5%] with at least 1 chronic comorbidity) were included in the study. At 28 days
after ICU admission, 784 patients (35.4%) had died, 824 (37.2%) were discharged, and 607
(27.4%) remained hospitalized. At the end of study follow-up (median, 16 days; interquartile
range, 8-28 days), 875 patients (39.5%) had died, 1203 (54.3%) were discharged, and 137
(6.2%) remained hospitalized. Factors independently associated with death included older
age (80 vs <40 years of age: odds ratio [OR], 11.15; 95% CI, 6.19-20.06), male sex (OR, 1.50;
95%CI, 1.19-1.90), higher bodymass index (40 vs <25: OR, 1.51; 95%CI, 1.01-2.25), coronary
artery disease (OR, 1.47; 95%CI, 1.07-2.02), active cancer (OR, 2.15; 95%CI, 1.35-3.43), and
the presence of hypoxemia (PaO2:FIO2<100 vs300mmHg: OR, 2.94; 95%CI, 2.11-4.08),
liver dysfunction (liver Sequential Organ Failure Assessment score of 2 vs 0: OR, 2.61; 95%CI,
1.30–5.25), and kidney dysfunction (renal Sequential Organ Failure Assessment score of 4 vs 0:
OR, 2.43; 95%CI, 1.46–4.05) at ICU admission. Patients admitted to hospitals with fewer ICU
beds had a higher risk of death (<50 vs100 ICU beds: OR, 3.28; 95%CI, 2.16-4.99). Hospitals
varied considerably in the risk-adjusted proportion of patients who died (range, 6.6%-80.8%)
and in the percentage of patients who received hydroxychloroquine, tocilizumab, and other
treatments and supportive therapies.
CONCLUSIONS AND RELEVANCE This study identified demographic, clinical, and hospital-level
risk factors that may be associated with death in critically ill patients with COVID-19 and can
facilitate the identification of medications and supportive therapies to improve outcomes.
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S ince the outbreak of severe acute respiratory syn-drome coronavirus 2 (SARS-CoV-2) infection began inDecember 2019 in Wuhan, China, more than 6 million
people have developed coronavirus disease 2019 (COVID-
19), and more than 350000 have died.1 Critical illness from
COVID-19 in China, Italy, and other countries has strained in-
tensive care unit (ICU) resources and produced a wide spec-
trumofshort-termmortality rates, ranging from16%to62%.2-4
As of June 19, 2020, approximately 2.2 million people in
the US have been infected with SARS-CoV-2, and more than
100000havedied.Althoughmorepeoplehavedied in theUS
than inanyother country,1 nationaldata are lackingon theepi-
demiologic factors, treatment, and outcomes of critical ill-
ness from COVID-19. One study5 of 24 patients in the Seattle,
Washington, region reported frequent receipt of invasive
mechanical ventilatory support and vasopressors and an
in-hospital mortality of 50%. Local outbreaks of COVID-19 in
New York City have been described in single-center and re-
gional reports.6,7 These studies6,7 includedprimarilynoncriti-
cally ill patients and had limited follow-up duration.
Granular data on patient characteristics, treatment, and
outcomes of critical illness from COVID-19 are needed to in-
formdecision-making about resource allocation, critical care
capacity, and treatment of patients. Furthermore, nationally
representativedata acrossmultiplehospitals areneeded toas-
sess interhospital variation in treatment andoutcomes. Toad-
dress thisknowledgegap,weconducted theStudyof theTreat-
ment and Outcomes in Critically Ill Patients With COVID-19
(STOP-COVID), amulticenter cohort study that examined the
demographics, comorbidities, organ dysfunction, treatment,
and outcomes of patients with COVID-19 admitted to ICUs
across the US. The purposes of this study were to assess fac-
tors associatedwithdeath and to examine interhospital varia-
tion in treatment and outcomes in patients with COVID-19.
Methods
Study Design andOversight
In this multicenter cohort study, we enrolled adults with
COVID-19whowere admitted to participating ICUs at 65 hos-
pitals. The study was approved by the institutional review
boardsat eachparticipating sitewithawaiverof informedcon-
sent. All data except dates were deidentified.
Study Sites and Patient Population
We included consecutive adult patients (≥18years of age)with
laboratory-confirmed COVID-19 (detected by nasopharyn-
geal or oropharyngeal swab) admitted to a participating ICU
for illness related to COVID-19 between March 4 and April 4,
2020. Patients were considered to have been admitted to an
ICU if they were admitted to a regular ICU or if they were in a
non-ICU room that was functioning as an ICU room for surge
capacity (defined further in the eMethods and eAppendix in
the Supplement). We followed up patients until hospital dis-
charge, death, or June 4, 2020, whichever came first. A com-
plete list of participating sites is provided in eTable 1 andeFig-
ures 1 and2 in theSupplement. In this cohort, 98patientswere
described in prior studies, including 58 reported in a single-
center case series fromNewYorkCity that includedboth criti-
cally ill and noncritically ill patients,6 28 reported in a single-
center study focusedon acute kidney injury,8 and 12 reported
in a case series of critically ill patients fromtheSeattle region.5
Outcomes
Theprimary outcomewasdeathwithin 28days of ICUadmis-
sion. Patientswhoweredischarged alive from thehospital be-
fore 28 dayswere considered to be alive at 28 days (we tested
the validity of this assumption in a subset of patients, de-
scribed in the eMethods in the Supplement). Secondary out-
comes included development of respiratory failure, acute
respiratory distress syndrome, congestive heart failure,myo-
carditis, pericarditis, arrhythmia, shock, acute cardiac injury,
acute kidney injury, acute liver injury, coagulopathy, second-
ary infection, and thromboembolic events (definitions pro-
vided in eTable 2 in the Supplement). We also examined
receipt of antivirals, antibiotics, anticoagulants, immuno-
modulatingmedications,mechanical ventilatory support, ad-
junctive and rescue therapies for hypoxemia, extracorporeal
membrane oxygenation, mechanical cardiac support, vaso-
pressors, and kidney replacement therapy.
Data Collection
Study personnel at each site collected data bymanual review
of electronic medical records and used a standardized case
report form to enter data into a secure online database
(eAppendix 2 in the Supplement). Patient-level data included
baseline information on demographics, coexisting condi-
tions, symptoms,medications beforehospital admission, and
vital signs; daily data for the 14 days after ICU admission on
physiologic and laboratory values, medications, nonmedica-
tion treatments, andorgan support; andoutcomedata on ICU
and hospital length of stay and death. We also collected hos-
pital-level data, including the city and state, main hospital vs
satellite or affiliate hospital for the center, the number of ICU
beds (not including surge capacity), and type of ICU towhich
thepatientswereadmitted (medical,COVIDspecific, orother).
All data were validated through a series of automated and
manual verifications (eMethods in the Supplement).
Key Points
Question What are the characteristics, outcomes, and factors
associated with death among critically ill patients with coronavirus
disease 2019 (COVID-19) in the US?
Findings In a cohort of 2215 adults with COVID-19 whowere
admitted to intensive care units at 65 sites, 784 (35.4%) died
within 28 days, with wide variation among hospitals. Factors
associated with death included older age, male sex, obesity,
coronary artery disease, cancer, acute organ dysfunction, and
admission to a hospital with fewer intensive care unit beds.
Meaning This study identified demographic, clinical, and
hospital-level factors associated with death in critically ill patients
with COVID-19 that may be used to facilitate the identification of
medications and supportive therapies that can improve outcomes.
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Statistical Analysis
We aimed to generate a representative sample of critically ill
adults by enrolling at least 2000patients fromat least 50geo-
graphically diverse hospitals. To describe baseline character-
istics, treatment, and outcomes, we express continuous vari-
ables as median (interquartile range [IQR]) and categorical
variables as number (percentage).
To assess interhospital variation in treatments and out-
comes,weusedmultilevel conditional logistic regressionmod-
elingwithpatientsnested inhospitals to characterizehospital-
level variation in treatment and to estimate hospital-specific
rates of death at 28days. This approach addresses thepoor re-
liability of estimates stemming fromhospitals that submitted
few cases. To further improve the reliability of the estimates,
we excluded hospitals that submitted data on fewer than 15
patients.
To account for differences in patient-level characteristics
and illness severity among hospitals, we prespecified the fol-
lowing covariates for inclusion in the models: age, sex, race,
hypertension,diabetes, bodymass index (calculatedasweight
in kilograms divided by height in meters squared), coronary
arterydisease,congestiveheart failure, chronicobstructivepul-
monary disease, current smoking status, active cancer, dura-
tion of symptoms before ICU admission, and covariates as-
sessed at ICU admission (lymphocyte count, ratio of the PaO2
to the fraction of inspired oxygen [FIO2], shock, and the kid-
ney, liver, and coagulation components of the Sequential
OrganFailureAssessment score).9We included theabovechar-
acteristics and patient-level deviations from hospital means
in themodels. Finally, in a sensitivity analysis, we further ad-
justed for the number of ICU beds at each hospital before the
COVID-19 pandemic (<50, 50-99, and ≥100 ICU beds).
To identify independent associationsbetweenpatient and
hospital characteristics and the primary outcome of 28-day
mortality, we again used multilevel logistic regression mod-
eling, with a random effect for hospital and fixed effects for
each variable of interest. We included the same covariates as
above.We also performed 2 sensitivity analyses. First, we re-
peated theaboveanalysisbut limited thepatients to thosewho
received invasive mechanical ventilatory support on ICU
day 1. Second, we used a Cox regression model and all avail-
able follow-updata toassess theassociationbetweentheabove
covariates and survival.
Data regarding body mass index were missing for 109
patients (4.9%). Data regarding the ratio of PaO2:FIO2 at ICU
admission were missing for 273 of 1494 patients (18.3%). Ad-
ditional details onmissing data are provided in the eMethods
and eTable 3 in the Supplement. Analyses were performed
using SAS software, version 9.4 (SAS Institute Inc) and Stata,
version 16.1 (StataCorp LLC).
Results
Patient Characteristics at Baseline
Fromthe65sites, 2215of2833patients initially consideredmet
eligibility criteria andwere included in the analysis. Themean
(SD)agewas60.5 (14.5) years, and1436 (64.8%)weremen.The
mediandurationof symptomsbefore ICUadmissionwas7days
(IQR, 4-10days). Themost commonsymptomsbefore ICUad-
mission were cough (1708 [77.1%]), dyspnea (1658 [74.9%]),
and fever (1566 [70.7%]). A total of 1738 patients (78.5%) had
at least 1 coexisting condition, including hypertension (1322
[59.7%]), diabetes (861 [38.9%]), and chronic lung disease
(531 [24.0%]). On the day of ICU admission, 1494 patients
(67.4%) received invasivemechanical ventilatory support, and
958 (48.3%) received vasopressors. The median PaO2:FIO2
ratio was 124 mm Hg (IQR, 86-188 mm Hg). Additional char-
acteristics are provided in Table 1 and eTables 3 and 4 and
eFigures 3 and 4 in the Supplement.
Acute Organ Injury
In the 14 days after ICU admission, 1859 patients (83.9%) re-
ceived invasive mechanical ventilatory support, 1635 pa-
tients (73.8%) developed acute respiratory distress syn-
drome, and 921 of the 2151 patientswithout end-stage kidney
disease (42.8%) developed acute kidney injury. Other acute
organ injuries were less frequent in this study, with only 230
patients (10.4%) experiencing a clinically detected thrombo-
embolic event. The incidence of other acute organ injuries is
shown in eFigure 5 in the Supplement.
The median time from symptom onset to each acute or-
gan injury is shown in eFigure 5 in the Supplement. Respira-
tory failure, acute cardiac injury, and congestive heart failure
occurred earlier in the illness, whereas secondary infection,
acute liver injury, and thromboembolic events occurred later
(eTable 5 in the Supplement). Longitudinal assessment of
laboratory values and physiologic parameters is shown in
eFigure 6 in the Supplement.
Treatment
The most commonly administered medications for COVID-
19–related illness were hydroxychloroquine (1761 [79.5%]),
azithromycin (1320 [59.6%]), and therapeutic anticoagulants
(920 [41.5%]). Interventions for hypoxemia included neuro-
muscular blockade (909 [41.0%]), prone positioning (852
[38.5%]), inhaled epoprostenol (118 [5.3%]), and inhaled
nitric oxide (94 [4.2%]). Additionalmedications and support-
ive therapies are listed in Table 2.
Risk- and reliability-adjusteduseofmedications and sup-
portive therapies variedwidely amonghospitals (Figure 1 and
eTable 6 in the Supplement). For example, the risk- and reli-
ability-adjustedproportionofpatientswho receivedhydroxy-
chloroquine was 82.2% overall but ranged from 16.8% at the
lowest usehospital to 98.1%at thehighest. Similarly, the risk-
and reliability-adjusted proportion of patients who received
prone positioning was 35.1% overall but ranged from 4.6% at
the lowest use hospital to 79.9% at the highest. Considerable
interhospitalvariation in theuseof therapiespersisted inanaly-
ses further adjusted for the number of ICU beds (eTable 6 in
the Supplement).
28-DayMortality
Overall, 784 patients (35.4%) died within 28 days of ICU ad-
mission, 824 (37.2%) were discharged alive from the hospital
within 28 days, and 607 (27.4%) remained hospitalized at
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Table 1. Patient Characteristics at Baselinea
Characteristic
All patients
(N = 2215)
Day 28
Alive
(n = 1431)
Died
(n = 784)
Demographics
Age, mean (SD), y 60.5 (14.5) 57.4 (14.2) 66.0 (13.3)
Male 1436 (64.8) 900 (62.9) 536 (68.4)
Race/ethnicity
White 837 (37.8) 549 (38.4) 288 (36.7)
Black 669 (30.2) 436 (30.5) 233 (29.7)
Asian 133 (6.0) 86 (6.0) 47 (6.0)
Other 576 (26.0) 360 (25.2) 216 (27.6)
Hispanic 445 (20.1) 288 (20.1) 157 (20.0)
BMI, median (IQR)b 30.5 (26.6-36.2) 30.7 (26.7-36.3) 29.9 (26.2-35.9)
Homeless 13 (0.6) 9 (0.6) 4 (0.5)
Symptoms before ICU admission
Cough 1708 (77.1) 1146 (80.1) 562 (71.7)
Sputum production 287 (13.0) 195 (13.6) 92 (11.7)
Dyspnea 1658 (74.9) 1084 (75.8) 574 (73.2)
Fever 1566 (70.7) 1051 (73.4) 515 (65.7)
Fatigue or malaise 720 (32.5) 482 (33.7) 238 (30.4)
Nausea or vomiting 391 (17.7) 282 (19.7) 109 (13.9)
Diarrhea 461 (20.8) 323 (22.6) 138 (17.6)
Time from symptom onset to ICU admission, median (IQR), d 7 (4-10) 8 (5-10) 7 (3-9)
Coexisting conditionsc
Any 1738 (78.5) 1053 (73.6) 685 (87.4)
Diabetes
Insulin dependent 305 (13.8) 170 (11.9) 135 (17.2)
Non–insulin dependent 556 (25.1) 339 (23.7) 217 (27.7)
Hypertension 1322 (59.7) 782 (54.6) 540 (68.9)
Chronic lung disease 531 (24.0) 334 (23.2) 197 (25.1)
COPD 173 (7.8) 86 (6.0) 87 (11.1)
Asthma 258 (11.6) 188 (13.1) 70 (8.9)
Other pulmonary disease 169 (7.6) 98 (6.8) 71 (9.1)
Current or former smoker 656 (29.6) 392 (27.4) 264 (33.7)
Coronary artery disease 288 (13.0) 130 (9.1) 158 (20.2)
Congestive heart failure 196 (8.8) 100 (7.0) 96 (12.2)
Chronic kidney disease 280 (12.6) 148 (10.3) 132 (16.8)
End-stage kidney disease 64 (2.9) 29 (2.0) 35 (4.5)
Active cancer 112 (5.1) 52 (3.6) 60 (7.7)
Immunodeficiency 65 (2.9) 38 (2.7) 27 (3.4)
Home medications
Immunosuppressive medication 251 (11.3) 150 (10.5) 101 (12.9)
ACE-I 401 (18.1) 247 (17.3) 154 (19.6)
ARB 365 (16.5) 208 (14.5) 157 (20.0)
Mineralocorticoid receptor antagonist 65 (2.9) 29 (2.0) 36 (4.6)
Statin 840 (37.9) 476 (33.3) 364 (46.4)
NSAID 191 (8.6) 130 (9.1) 61 (7.8)
Aspirin 491 (22.2) 257 (18.0) 234 (29.8)
Anticoagulation 186 (8.4) 107 (7.5) 79 (10.1)
Vital signs on the day of ICU admission, median (IQR)
Temperature, °C 38.1 (37.3-38.9) 38.1 (37.4-38.9) 38.0 (37.3-38.9)
Systolic blood pressure, mm Hgd 96 (86-111) 98 (87-111) 94 (83-109)
Heart rate, /mine 104 (90-119) 102 (90-116) 106 (92-123)
(continued)
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28 days. The unadjusted incidence of deathwithin 28 days of
ICUadmissionisdisplayedaccordingtobaselinepatientandhos-
pital characteristics in eFigures 3 and4 in the Supplement and
according togeographic region ineFigure7 in theSupplement.
The most common causes of death were respiratory failure
(727 [92.7%]), septic shock (311 [39.7%]), and kidney failure
(295 [37.6%]), withmany patients havingmore than 1 cause.
Risk- and reliability-adjusted rate of death within 28
days varied widely across hospitals, from 6.6% to 80.8%
(eFigure 8 and eTable 6 in the Supplement). After further ad-
justment for the number of ICU beds before the pandemic,
this variation decreased, such that the risk- and reliability-
adjusted rate of death ranged from 11.9% to 63.3% (eTable 6
in the Supplement).
In a multivariable model that examined the association
betweenprespecifiedpatient andhospital characteristics and
28-daymortality, older agewas independentlyassociatedwith
higher risk of death (≥80 vs <40 years of age: odds ratio [OR],
11.15; 95% CI, 6.19-20.06) (ORs for other age categories are
shown inFigure 2). Additional characteristics associatedwith
deathweremale sex (OR, 1.50; 95%CI, 1.19-1.90), higher body
mass index (≥40 vs <25: OR, 1.51; 95%CI, 1.01-2.25), coronary
arterydisease (OR, 1.47; 95%CI, 1.07-2.02), active cancer (OR,
2.15; 95%CI, 1.35-3.43), and thepresence of hypoxemia (PaO2:
FIO2<100 vs ≥300 mm Hg: OR, 2.94; 95% CI, 2.11-4.08), liver
dysfunction (liver Sequential OrganFailureAssessment score
of 2 vs 0: OR, 2.61; 95% CI, 1.30–5.25), and kidney dysfunc-
tion (renal Sequential Organ Failure Assessment score of 4 vs
0: OR, 2.43; 95% CI, 1.46–4.05) at ICU admission (Figure 2).
Race (race other than White vs White race: OR, 1.11; 95% CI,
0.88-1.40), hypertension (OR, 1.06; 95%CI, 0.83-1.36), diabe-
tes (OR, 1.14; 0.91-1.43), and lymphocyte count (OR, 1.11; 95%
CI, 0.88-1.41)were not associatedwith death. Patients admit-
ted tohospitalswith fewer ICUbedshad ahigher risk of death
(<50vs≥100 ICUbeds;OR, 3.28; 95%CI, 2.16-4.99) (Figure 2).
Interpretationswere largelyunchangedwhen restricted topa-
tients who received invasive mechanical ventilatory support
on ICU day 1 (eFigure 9 in the Supplement), although a body
mass index greater than 40 was no longer associated with
a higher risk of death.
Other Clinical Outcomes
Among patients discharged alive from the hospital within
28 days of ICU admission, the median ICU length of stay was
9 days (IQR, 5-14 days) and themedian hospital length of stay
was 16 days (IQR, 11-22 days). Extracorporeal organ support
Table 1. Patient Characteristics at Baselinea (continued)
Characteristic
All patients
(N = 2215)
Day 28
Alive
(n = 1431)
Died
(n = 784)
Laboratory findings on the day of ICU admission, median (IQR)
White blood cell count, /μLf 7900 (5800-11 200) 7700 (5800-10 600) 8300 (5900-12 000)
Lymphocyte count, /μL 811 (552-1144) 842 (582-1159) 747 (497-1091)
Hemoglobin level, g/dLg 12.7 (11.2-14.1) 12.8 (11.4-14.1) 12.6 (10.9-14.0)
Creatinine level, mg/dLh 1.0 (0.8-1.5) 1.0 (0.8-1.3) 1.2 (0.9-2.0)
D-dimer level, ng/mLi 1190 (690-2700) 1076 (652-2310) 1643 (877-3980)
C-reactive protein level, mg/Lj 158 (94-237) 153 (87-228) 174 (104-258)
Severity of illness on the day of ICU admission
Invasive mechanical ventilatory support, median (IQR) 1494 (67.4) 889 (62.1) 605 (77.2)
FIO2k 0.8 (0.6-1.0) 0.8 (0.5-1.0) 1.0 (0.6-1.0)
PEEP, cm H2Ol 12 (10-15) 12 (10-15) 12 (10-15)
PaO2:FIO2, mm Hgm 124 (86-188) 131 (92-195) 113 (80-181)
Noninvasive mechanical ventilation 27 (1.2) 19 (1.3) 8 (1.0)
High-flow nasal cannula or nonrebreather mask 410 (18.5) 293 (20.5) 117 (14.9)
Vasopressor treatment 958 (48.3) 584 (40.8) 374 (47.7)
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor;
ARB, angiotensin II receptor blocker; BMI, bodymass index (calculated as
weight in kilograms divided by height in meters squared); COPD, chronic
obstructive pulmonary disease; ICU, intensive care unit; IQR, interquartile
range; NSAID, nonsteroidal anti-inflammatory drug; PaO2:FIO2, ratio of PaO2
over the fraction of inspired oxygen (assessed only in patients receiving invasive
mechanical ventilation); PEEP, positive end-expiratory pressure.
SI conversion factors: to convert white blood cells and lymphocytes to ×109/L,
multiply by 0.001; hemoglobin to grams per liter, multiply by 10; creatinine to
micromoles per liter, multiply by 88.4; D-dimer to nanomoles per liter, multiply
by 5.476; and C-reactive protein to milligrams per liter, multiply by 10.
a Data are presented as number (percentage) of patients unless otherwise
indicated.
bData regarding BMI weremissing for 109 patients (4.9%).
c The definitions of the coexisting conditions are provided in the eMethods in
the Supplement.
dData regarding systolic blood pressure weremissing for 1 patient (0.05%).
e Data regarding heart rate were missing for 1 patient (0.05%).
f Data regarding white blood cell count were missing for 105 patients (4.7%).
g Data regarding hemoglobin level were missing for 110 patients (5.0%).
hData regarding creatinine level were missing for 88 patients (4.0%).
i Data regarding D-dimer level were missing for 1186 patients (53.5%).
j Data regarding C-reactive protein level were missing for 917 patients (41.4%).
k Data regarding FIO2 were missing for 178 of 1494 patients (11.9%) receiving
invasive mechanical ventilatory support.
l Data regarding PEEPweremissing for 185 of 1494 patients (12.4%) receiving
invasive mechanical ventilatory support.
mData regarding PaO2:FIO2 were missing for 273 of 1494 patients (18.3%)
receiving invasive mechanical ventilatory support.
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included acute kidney replacement therapy (432 [20.1%]),
extracorporeal membrane oxygenation (61 [2.8%]), and me-
chanical cardiac support (3 [0.1%]). Additional outcomes are
provided in Table 3.
Mortality and Length of Stay Beyond 28Days
At the end of study follow-up (median, 16 days; interquartile
range,8-28days), a total of875patients (39.5%)haddied, 1203
(54.3%)weredischargedalive fromthehospital, and137 (6.2%)
remainedhospitalized.Amongpatients discharged alive from
the hospital, the median ICU length of stay was 12 days (IQR,
6-21 days), and themedianhospital length of staywas 21 days
(IQR, 13-33days). Using amultivariableCox regressionmodel,
we identified factors associated with death that were similar
to those in the 28-day mortality model (eFigure 10 in the
Supplement).
Discussion
This multicenter cohort study of 2215 critically ill adults with
COVID-19 admitted to ICUs at 65 hospitals across theUS found
that784patients (35.4%)diedinthe28daysafter ICUadmission.
Olderage,malesex,higherbodymassindex,coronaryarterydis-
ease, and active cancer were independently associated with a
higher riskofdeath,aswas thepresenceofhypoxemiaand liver
andkidneydysfunctionat ICUadmission.Patients admitted to
hospitalswithfewerICUbedsalsohadahigherriskofdeath.Hos-
pitals variedwidely in the proportion of patientswho received
medicationsandsupportivetherapyforCOVID-19andinthepro-
portion of patientswho died.
Prior data on critical illness from COVID-19 derive from
cohorts in China and Italy and small case series and regional
Table 2. Medications and Supportive Therapies for Coronavirus Disease 2019a
Treatment
Patients, No. (%)
All patients
(N = 2215)
Day 28
Alive
(n = 1431)
Died
(n = 784)
Antibiotics and antivirals
Hydroxychloroquine 1761 (79.5) 1130 (79.0) 631 (80.5)
Azithromycin 1320 (59.6) 863 (60.3) 457 (58.3)
Hydroxychloroquine and azithromycin 1117 (50.4) 729 (50.9) 388 (49.5)
Chloroquine 29 (1.3) 17 (1.2) 12 (1.5)
Remdesivir 134 (6.1) 101 (7.1) 33 (4.2)
Lopinavir and ritonavir 83 (3.8) 49 (3.4) 34 (4.3)
Therapeutic anticoagulationb
Any 920 (41.5) 570 (39.8) 350 (44.6)
Heparin drip 573 (25.9) 349 (24.4) 224 (28.6)
Enoxaparin 302 (13.6) 206 (14.4) 96 (12.2)
Bivalirudin 25 (1.1) 19 (1.3) 6 (0.8)
Argatroban 24 (1.1) 16 (1.1) 8 (1.0)
Anti-inflammatory medications
Corticosteroids 800 (36.1) 443 (31.0) 357 (45.5)
NSAIDs 99 (4.5) 76 (5.3) 23 (2.9)
Aspirin 377 (17.0) 205 (14.3) 172 (21.9)
Statins 519 (23.4) 336 (23.5) 183 (23.3)
Tocilizumab 378 (17.1) 265 (18.5) 113 (14.4)
Other interleukin 6 inhibitors 15 (0.7) 8 (0.6) 7 (0.9)
Vitamin C 196 (8.9) 120 (8.4) 76 (9.7)
Other medications
Convalescent plasma 14 (0.6) 14 (1.0) 0 (0)
ACE-I 61 (2.8) 50 (3.5) 11 (1.4)
ARB 66 (3.0) 51 (3.6) 15 (1.9)
Tissue plasminogen activator 27 (1.2) 13 (0.9) 14 (1.8)
Specific interventions for hypoxemia
Prone position 852 (38.5) 519 (36.3) 333 (42.5)
Neuromuscular blockade 909 (41.0) 524 (36.6) 385 (49.1)
Inhaled epoprostenol 118 (5.3) 62 (4.3) 56 (7.1)
Inhaled nitric oxide 94 (4.2) 71 (5.0) 23 (2.9)
Enrolled in a clinical trialc 398 (18.0) 298 (20.9) 100 (12.8)
Abbreviations: ACE-I,
angiotensin-converting enzyme
inhibitor; ARB, angiotensin II receptor
blocker; ICU, intensive care unit;
NSAIDs, nonsteroidal
anti-inflammatory drugs.
a Each of the interventions was
assessed during the 14 days after
ICU admission.
bData on therapeutic anticoagulation
weremissing for 10 patients (0.5%).
c Data on enrollment in a clinical trial
were missing for 8 patients (0.4%).
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reports from cohorts in the US.3-6 Compared with a large co-
hort of critically ill patientswithCOVID-19 in Lombardy, Italy,
the median age of patients in the cohort in the present study
and the proportion who received invasive mechanical venti-
latory supportwere similar.4 Themortality in the cohort in the
present studywashigher than thatof critically ill patientswith
COVID-19 in Italy (26%),4 although 58%of the patients in that
cohort were still in the ICU at the end of follow-up, but lower
than that reported in single-center studies fromWuhan,China
(62%)3 and the Seattle region of the US (50%).5 These com-
parisons are limited by different ICU admitting practices and
duration of follow-up among studies.
Themost commonacuteorgan injuriesobserved in theco-
hort in this study were respiratory failure, acute respiratory
distress syndrome, and acute kidney injury. Other acute
organ injuries were less frequent in this study, with only 230
patients (10.4%) experiencing a clinically detected thrombo-
embolic event. This incidence of thromboembolic events is
considerably lower than the 15% to42% incidence reported in
critically ill patientswithCOVID-19 inEurope10-14 and ismore
consistent with the incidence reported in critically ill pa-
tientswithoutCOVID-19.15Understanding the reason for these
differenceswillbe importantashypercoagulability inCOVID-19
is pursued as a potential therapeutic target.16
This study identified considerable interhospital varia-
tion in theadministrationofmedicationsandsupportive thera-
pies intended to treat COVID-19 and associated organ injury.
Sources of this variation may include the limited high-
quality evidence on which to base clinical practice, variation
inhospital resources to implement personnel-intensive inter-
ventions (eg, prone positioning), variation in the availability
of certainmedications (eg, remdesivir), or unmeasuredvaria-
tion in patient andpractitioner characteristics across centers.
These data support clinical equipoise for ongoing random-
ized clinical trials of therapies for COVID-19.
In this study, several patient characteristics were associ-
atedwithahigher riskofdeath. Similar toprevious reports,17,18
older agewas associatedwith a higher risk of death, although
at least 15%ofpatientsdied ineveryagegroup, including those
younger than 40 years. Two-thirds of the patients weremen,
andmale sexwas independently associatedwith ahigher risk
of death, supporting a prior report19 of the association be-
Figure 1. Interhospital Variation in Treatments
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tweenmale sexandadverseoutcomes inpatientswithCOVID-
19. In addition,we found that higher bodymass indexwas in-
dependently associatedwith ahigher risk of death, extending
the findings from prior reports20-22 on the association be-
tweenobesity and severe illness fromCOVID-19.Wealso iden-
tified severalnovelpatient-level factors associatedwithdeath,
including coronary artery disease and active cancer. Finally,
we found that patients who were admitted to hospitals with
fewer ICU beds had a higher risk of death.
Nearly 1 in 3patients in thepresent cohortwasBlack com-
pared with approximately 13.4% of the US population. Race,
however,wasnot associatedwithdeath inmultivariablemod-
els. These results are similar to those recently reported by
a single-center study23 in Louisiana, which found that Black
Figure 2. Multivariable-Adjusted RiskModel for Death at 28 Days
0.5 4 162 8
Odds ratio (95% CI)
1
Decreased
risk of death
Increased
risk of deathCharacteristic
Age group, y
Odds ratio (95% CI)
for death
≥80 
Male sex 1.50 (1.19-1.90)
Race other than White
Hypertension
Diabetes
BMI
<25
25-29.9
30-34.9
35-39.9
≥40
Coronary artery disease
Congestive heart failure
Chronic obstructive pulmonary disease
Current smoker
Active cancer
≤3 d From symptom onset to ICU day 1
Lymphocyte count <1000/μL on ICU day 1
PaO2:FiO2 on ICU day 1
Not receiving IMV support
≥300
200-299
100-199
<100
Shock on ICU day 1
Coagulation component of SOFA score
0
1
2
Liver component of SOFA score
0
1
2
Renal component of SOFA score
0
1
2
3
4
No. of ICU beds
High (≥100)
Medium (50-99)
Low (<50)
1.11 (0.88-1.40)
1.06 (0.83-1.36)
1.14 (0.91-1.43)
1 [Reference]
1.01 (0.73-1.39)
0.97 (0.69-1.37)
1.24 (0.81-1.89)
1.51 (1.01-2.25)
1.47 (1.07-2.02)
1.08 (0.75-1.58)
1.39 (0.95-2.04)
1.21 (0.76-1.93)
2.15 (1.35-3.43)
1.29 (0.99-1.67)
1.11 (0.88-1.41)
1 [Reference]
1.49 (0.95-2.33)
1.72 (1.13-2.63)
2.13 (1.58-2.87)
2.94 (2.11-4.08)
0.84 (0.60-1.19)
1 [Reference]
1.20 (0.89-1.63)
1.64 (1.00-2.69)
1 [Reference]
1.07 (0.72-1.58)
2.61 (1.30-5.25)
1 [Reference]
1.56 (1.20-2.02)
1.89 (1.26-2.84)
2.01 (1.18-3.42)
2.43 (1.46-4.05)
1 [Reference]
1.67 (1.10-2.53)
3.28 (2.16-4.99)
11.15 (6.19-20.06)
18-39 1 [Reference]
40-49 1.65 (0.97-2.80)
50-59 1.71 (1.05-2.80)
60-69 3.18 (1.95-5.18)
70-79 5.36 (3.20-9.00)
To convert lymphocytes to ×109/L,
multiply by 0.001. BMI, bodymass
index (calculated as weight in
kilograms divided by height in meters
squared); ICU, intensive care unit;
IMV, invasive mechanical ventilation;
PaO2:FIO2, ratio of the PaO2 over the
fraction of inspired oxygen; SOFA,
Sequential Organ Failure Assessment.
Research Original Investigation Factors AssociatedWith Death in Critically Ill Patients With Coronavirus Disease 2019
E8 JAMA Internal Medicine Published online July 15, 2020 (Reprinted) jamainternalmedicine.com
© 2020 American Medical Association. All rights reserved.
patients were more likely to be hospitalized but had similar
in-hospitalmortality comparedwithWhite patients. The rea-
sons forpotential racial differences in the frequencyof ICUad-
mission with COVID-19 are likely multifactorial and may re-
flect differences in comorbidities, socioeconomic status, and
other factors.
Strengths and Limitations
This study has several strengths. First, we collected compre-
hensive data from a large number of consecutive critically ill
patients with laboratory-confirmed COVID-19 for 28 days,
therebyminimizing selectionor surveillance bias at each cen-
ter. Second, we included patients from 65 geographically di-
verse sites from across the US, thereby maximizing general-
izability. By including a large number of hospitals, we also
identified considerable variation in risk-adjustedpracticepat-
terns and outcomes across sites. Third, we obtained all data
by detailedmedical record review rather than reliance on ad-
ministrative or billing codes, which have well-described
limitations.24Fourth,whereasprior studies4-7 followeduppa-
tients for shorterperiods,we followeduppatientsuntil the first
occurrence of hospital discharge, death, or 28 days in our pri-
mary analyses and for up to 3months in secondary analyses.
By including additional follow-up, we were able to ascertain
a definitive in-hospital mortality outcome (death or dis-
charged) in 93.8% of the patients in our cohort. With the ad-
ditional follow-up, the in-hospital mortality rate was 39.5%.
Weacknowledge several limitations.Althoughhealth care
center was included as a covariate in multivariable models,
there may be unmeasured differences in patient populations
among hospitals, explaining some of the observed variation
in treatments and outcomes. Although some acute organ in-
juries (eg, acute kidney, liver, and cardiac injury) were as-
sessed by objective laboratory-based definitions, others (eg,
acute respiratory distress syndrome) relied on the clinical im-
pressionof the treatingpractitionerandmayhavedifferedfrom
the true incidence.Althoughweassessedmortality and length
of stay for 28 days, we assessed laboratory and physiologic
Table 3. Clinical Outcomes andOrgan Supporta
Variable
All patients
(N = 2215)
Day 28
Alive
(n = 1431)
Died
(n = 784)
Primary outcome
Died within 28 d 784 (35.4) NA 784 (100)
Causes of deathb
Respiratory failure NA NA 727 (92.7)
Heart failure NA NA 78 (9.9)
Septic shock NA NA 311 (39.7)
End-stage kidney disease NA NA 294 (37.5)
Liver failure NA NA 38 (4.8)
Other NA NA 116 (14.8)
Discharged alive from the hospital by day 28 824 (37.2) 824 (57.6) NA
ICU length of stay, median (IQR), d NA 9 (5-14) NA
Hospital length of stay, median (IQR), d NA 16 (11-22) NA
Remained hospitalized 607 (27.4) 607 (42.4) NA
Mechanical ventilatory support on days 1-14
Received mechanical ventilatory support 1859 (83.9) 1126 (78.7) 733 (93.5)
Extubated, No./total No. (%)c 624/1859 (33.6) 506/1126 (44.9) 118/733 (16.1)
Length of mechanical ventilatory support,
median (IQR), d
11 (7-14) 13 (9-14) 9 (5-13)
ECMO (days 1-14)
Received ECMO 61 (2.8) 51 (3.6) 10 (1.3)
Decannulated from ECMO, No./total No. (%)c 9/61 (17.7) 9/51 (17.6) 0/10 (0)
Duration of ECMO, median (IQR), d 9 (7-12) 9 (8-12) 2.5 (1-9)
Acute kidney replacement therapy (days 1-14)d
Received acute kidney replacement therapy 432/2151 (20.1) 204/1402 (14.6) 228/749 (30.4)
Kidney replacement therapy discontinued,
No./total No. (%)c
124/432 (28.7) 55/204 (27.0) 69/228 (30.3)
Length of acute kidney replacement therapy,
median (IQR), d
7 (3-11) 9 (6-12) 5 (2-9)
Vasopressor treatment on days 1-14
Received vasopressors 1617 (73.0) 948 (66.2) 669 (85.3)
Vasopressor treatment discontinued, No./total
No. (%)c
909/1617 (56.2) 691/948 (72.9) 218/669 (32.6)
Length of vasopressor treatment, median (IQR), d 6 (3-9) 6 (3-9) 6 (3-9)
Mechanical cardiac support (days 1-14)e 4 (0.2) 3 (0.2) 1 (0.1)
Abbreviations: ECMO, extracorporeal
membrane oxygenation;
ICU, intensive care unit;
IQR, interquartile range; NA, not
applicable.
a Data are presented as number
(percentage) of patients unless
otherwise indicated.
bDefined as per medical record
review.
c Extubation, decannulation from
ECMO, and discontinuation of
kidney replacement therapy
included both patients determined
by treating practitioners to no
longer require these therapies and
patients for whom further
supportive therapy was declined as
a part of transition to comfort care.
d Patients with end-stage kidney
disease (n = 64) were excluded
from the denominator for analyses
of acute kidney replacement
therapy.
e Mechanical cardiac support
included left ventricular assist
device (n = 2) and right ventricular
assist device (n = 2).
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parameters, acute organ injury, andorgan support for the first
14 days only after ICU admission.
Our estimates of interhospital variation in risk- and reli-
ability-adjusted ratesofdeathmaybeaffectedby residual con-
founding because of differences in baseline risk and patient
andphysiciancharacteristics acrosshospitals thatwerenot ac-
counted for by our measured covariates. For example, other
than data on homelessness (0.6% prevalence in our cohort),
wedid not collect data on the socioeconomic status of the pa-
tients. Socioeconomic status is increasingly recognized as an
important factor associatedwith health outcomes in patients
withCOVID-1925 and could have influenced our findingswith
respect to variation inmortality across hospitals. We also did
not collect detailed data on ventilator management strate-
gies, hospital or ICU patient volume, or physician and nurse
availability. Ourmodels donot account for varyingdegrees of
strain on the available resources across hospitals, such as the
extent towhich itmayhave increased thenumber of ICUbeds
beyond thebaselinenumber before thepandemic.Wedidnot
collect dataondo-not-resuscitateordo-not-intubateordersor
theavailabilityofpalliativecare forpatients.These factorsmay
have contributed to differing rates of intubation and ICU ad-
mission, and thus mortality, across centers. Accordingly, our
findings should be interpreted cautiously. Further studies
should build on our findings and seek to better understand
the reasons for the considerable interhospital variation in
outcomes that we observed.
Conclusions
In this multicenter cohort study of critically ill adults with
COVID-19 in theUS,more than 1 in 3 diedwithin 28 days after
ICU admission. We identified several patient- and hospital-
level factors that were associated with death and found
that treatment and outcomes varied considerably among
hospitals. Future research should examine the patients
with COVID-19 at greatest risk of adverse outcomes and seek
to identify medications or supportive therapies that improve
their outcomes.
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